Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model

BackgroundTumor angiogenesis is a highly regulated process involving intercellular communication as well as the interactions of multiple downstream signal transduction pathways. Disrupting one or even a few angiogenesis pathways is often insufficient to achieve sustained therapeutic benefits due to the complexity of angiogenesis. Targeting multiple angiogenic pathways has been increasingly recognized as a viable strategy. However, translation of the polypharmacology of a given compound to its antiangiogenic efficacy remains a major technical challenge. Developing a global functional association network among angiogenesis-related genes is much needed to facilitate holistic understanding of angiogenesis and to aid the development of more effective anti-angiogenesis therapeutics.ResultsWe constructed a comprehensive gene functional association network or interactome by transcript profiling an in vitro angiogenesis model, in which human umbilical vein endothelial cells (HUVECs) formed capillary structures when co-cultured with normal human dermal fibroblasts (NHDFs). HUVEC competence and NHDF supportiveness of cord formation were found to be highly cell-passage dependent. An enrichment test of Biological Processes (BP) of differentially expressed genes (DEG) revealed that angiogenesis related BP categories significantly changed with cell passages. Built upon 2012 DEGs identified from two microarray studies, the resulting interactome captured 17226 functional gene associations and displayed characteristics of a scale-free network. The interactome includes the involvement of oncogenes and tumor suppressor genes in angiogenesis. We developed a network walking algorithm to extract connectivity information from the interactome and applied it to simulate the level of network perturbation by three multi-targeted anti-angiogenic kinase inhibitors. Simulated network perturbation correlated with observed anti-angiogenesis activity in a cord formation bioassay.ConclusionWe established a comprehensive gene functional association network to model in vitro angiogenesis regulation. The present study provided a proof-of-concept pilot of applying network perturbation analysis to drug phenotypic activity assessment.

[1]  J. Marx Encouraging Results for Second-Generation Antiangiogenesis Drugs , 2005, Science.

[2]  Tommi S. Jaakkola,et al.  Combining Location and Expression Data for Principled Discovery of Genetic Regulatory Network Models , 2001, Pacific Symposium on Biocomputing.

[3]  J. Folkman,et al.  CDK2 translational down-regulation during endothelial senescence. , 2005, Experimental cell research.

[4]  Nir Friedman,et al.  Inferring subnetworks from perturbed expression profiles , 2001, ISMB.

[5]  J. Folkman Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[6]  Rainer Breitling,et al.  Network theory to understand microarray studies of complex diseases. , 2006, Current molecular medicine.

[7]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[8]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[9]  J. Marx Cancer. Encouraging results for second-generation antiangiogenesis drugs. , 2005, Science.

[10]  H. Wakelee,et al.  Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. , 2006, Drugs of today.

[11]  D. Kurz,et al.  Endothelial cell senescence. , 2006, Handbook of experimental pharmacology.

[12]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[13]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[14]  R. Kerbel Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[15]  S. Hayward,et al.  Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Folkman,et al.  Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin , 2006, Science's STKE.

[17]  G. Jayson,et al.  A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis , 2006, Expert opinion on therapeutic targets.

[18]  Philip Hahnfeldt,et al.  Transcriptional network governing the angiogenic switch in human pancreatic cancer , 2007, Proceedings of the National Academy of Sciences.

[19]  Patrik D'haeseleer,et al.  Genetic network inference: from co-expression clustering to reverse engineering , 2000, Bioinform..

[20]  J. Folkman,et al.  Maintenance of G1 Checkpoint Controls in Telomerase-Immortalized Endothelial Cells , 2004, Cell cycle.

[21]  P. Carmeliet,et al.  Common mechanisms of nerve and blood vessel wiring , 2005, Nature.

[22]  D. Bagger-sjöbäck,et al.  An In Vitro Model , 1987 .

[23]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[24]  D. Jäger,et al.  [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[25]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[26]  Sanjay Mehrotra,et al.  A model-based optimization framework for the inference of regulatory interactions using time-course DNA microarray expression data , 2007, BMC Bioinformatics.

[27]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. R. Koehler,et al.  Modern Applied Statistics with S-Plus. , 1996 .

[29]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[30]  E. Passegué,et al.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.

[31]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[32]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[33]  Michael Krauthammer,et al.  Probabilistic inference of molecular networks from noisy data sources , 2004, Bioinform..

[34]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[35]  R. Albert,et al.  The large-scale organization of metabolic networks , 2000, Nature.

[36]  L. Akslen,et al.  Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.

[37]  M. Wirth,et al.  The ratio of formation of prostacyclin/thromboxane A2 in HUVEC decreased in each subsequent passage. , 1997, Prostaglandins.

[38]  P. Solenberg,et al.  Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model , 2006, Arthritis research & therapy.

[39]  A. Sartore-Bianchi,et al.  Rationale and Clinical Results of Multi-target Treatments in Oncology , 2007, The International journal of biological markers.

[40]  R. Kerbel Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. , 2005, Cancer cell.

[41]  David Liu,et al.  DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis , 2007, BMC Bioinformatics.

[42]  Denys N. Wheatley,et al.  An in vitro model of angiogenesis: Basic features , 2004, Angiogenesis.

[43]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[44]  G. Soff,et al.  Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.

[45]  D. Pe’er,et al.  Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data , 2003, Nature Genetics.